The Role of STAG2, CDKN2A, and TP53 Genes in Ewing Sarcoma: A Report of a Rare Case of Primary Ewing Sarcoma of the Kidney With Favorable Outcome.
Alyssa M Greenwell, Avanti Gupte, Ali G Saad et al.
✦ AI-curated · Sources linked
Case in brief
A pediatric patient presented with stage IV primary Ewing sarcoma of the kidney, a rare and aggressive malignancy. The patient underwent upfront surgical resection followed by radiation therapy, resulting in a durable remission lasting 4.5 years. The case highlights the potential impact of treatment strategies on outcomes in renal Ewing sarcoma.
What made this case unusual
The absence of specific genomic signatures (STAG2, CDKN2A, and TP53) in this case may have contributed to the favorable outcome, which is atypical for stage IV Ewing sarcoma.
Diagnostic / clinical pearl
Clinicians should consider the role of genomic markers and aggressive local control strategies in managing renal Ewing sarcoma, as they may influence patient outcomes.
Why it matters
This case underscores the need for further research into the biological behavior of renal Ewing sarcoma and the potential for improved outcomes with tailored treatment approaches.